Announced Date: 2020-09-04 (September 04, 2020)
Asset Name: Lemzoparlimab (TJC4)
Licensor (Seller): I-MAB Biopharma (China)
Licensee (Buyer): AbbVie
.
Asset Modality: monoclonal antibody
Asset Target: CD47
Potential Indication: solid tumor
Stage until the deal: Phase 1
.
Scope of Authority:
AbbVie will be granted an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab.
I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland China, Macau and Hong Kong.
Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers.
.
The collaboration also allows for potential collaboration on future CD47-related therapeutic agents. Each party will have the opportunity subject to further licenses to explore each other’s related programs in their respective territories.
The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The collaboration will accelerate I-Mab’s establishment of commercial production operations in China.
.
Payment Detail:
AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab,
along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million.
In addition, I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments for lemzoparlimab, of which $840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones.
Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.
.
Link:
.
Note:
Chinese Name of “I-MAB Biopharma“，天境生物
